BIA blog

TechBio innovator spotlight: BIOS

BIOS is leveraging the nervous system to inform treatments and deliver therapies for chronic conditions. The company uses AI and machine learning technology to tap into the nervous system which acts as the controlling, regulatory and communication system for the body, connecting all organs to the brain and spinal cord.

Meet the Psychiatry Consortium: Driving advances in drug discovery for mental health conditions

Dr Ekta Patel is Psychiatry Consortium Partnership Manager at Medicines Discovery Catapult. Ekta provides in-depth support to Psychiatry Consortium collaborators to develop and deliver the portfolio of projects. Read her blog about driving advances in our knowledge of disease biology for mental health conditions.

CEO Update | 28 November 2022

Thank you to all who have joined our BIA campaign to seek a solution to cuts in SME R&D tax credits introduced in the Autumn Statement. Today I was able to raise our concerns personally by handing a letter signed by over 300 CEOs to the Health Secretary and the Business Secretary at a meeting in Number 10 who assured me that this issue is being taken seriously at the very top of government.

CEO Update | 21 November 2022

A great week of UK life science connectivity at and around the Jefferies conference last week had the rug pulled from under it by government proposals in Thursday’s Autumn Statement to radically cut R&D tax credits for small and medium-sized companies from next April. We were able to provide immediate expert analysis of the implications of this proposal to Treasury officials last week. I will also be raising this with Ministers at the Life Sciences Council next Monday.

 

Member News

Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform

Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses.

Brainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solution

Brainomix to distribute Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe. The emergence of disease-modifying drugs now offers more personalized treatment of multiple sclerosis, a neurological disorder that affects more than 2.3 million people worldwide. This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.

Arecor to commence second clinical trial with AT278 ultra-concentrated ultra-rapid acting insulin candidate for Type 2 diabetes

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population.

ACROBiosystems collaborates with Carterra to enable large-scale characterization of potential drug candidates

Through the combination of ACROBiosystems’ high-quality multi-pass transmembrane proteins and Carterra’s innovative LSA platform, large-scale comprehensive characterization of drug candidates using high-throughput surface plasmon resonance (HT-SPR) can be rapidly performed.

 

Latest resources

Here's a selection of featured BIA publications. See Resources Hub  

BIA submission to MHRA fees consultation

BIA submission to the science and technology committee's inquiry on the governance of AI

The BIA has responded to the Science and technology select commitee's inquiry on the governance of artificial intelligence (AI).

 

Press Releases

Call to place medical and health research at the heart of economic plans

Ahead of the Autumn Statement, the Academy of Medical Sciences has led a call for the Chancellor to place medical and health research at the heart of plans for growth. The letter, signed by leading biomedical and health research institutions from the private and charitable sector including Pfizer, Wellcome, BioIndustry Association, Cancer Research UK and the British Heart Foundation, highlights the need to invest in research as a driver for health and wealth across the UK and globally.

UK biotechs enjoy best fundraising quarter of 2022

UK-based life sciences and biotech companies have raised ÂŁ1.5 billion in equity finance in the first three quarters of the year, with investment activity accelerating in the three months leading to 31 August.

BIA celebrates breaking 500 members after Moderna enters membership

The BioIndustry Association (BIA) today has announced that its membership has passed 500 companies, as mRNA global player Moderna entered into the trade association’s membership.

Mini-Budget positions UK life sciences to drive new government's economic growth agenda

The Chancellor of the Exchequer today announced at the mini-Budget the Long-Term Investment for Technology & Science (LIFTS) competition. This will provide up to £500 million to support new funds designed to catalyse investment from pensions schemes and other investors into the UK’s pioneering science and technology businesses, this is a direct result of the life science scale up agenda that the BIA has championed and worked closely with government on.